Document:

exmo_ex101.htm

    
      THIS
TECHNOLOGY LICENCE AGREEMENT (the "Agreement") is made the 8th day of June
2008.

       

      Between:

       

      (1)   David
Bychkov, founder and inventor of the BT2 technology, on individual whose address is at 7432
Emerald
Drive, Manassas, Virginia
(hereinafter called "the Licensor") of
the first part; 

       

      And

      

      
        (2)   BT2
International,
Inc., a company incorporated in Nevada whose registered office is
at Suite
2067, 1117 Desert Lane, Las Vegas, NV 89102-0000 (hereinafter called "the Licensee")
of the second part.

      

      
      

       

      WHEREAS:

      

      
        A.    The Licensor has developed and is the
sole and exclusive owner of the Intellectual Property Rights in the Technology
(as these terms are defined herein).

           

          A.    The Licensee wishes to obtain a licence
to use the Technology for the purpose of fabricating and manufacturing products
from the Patents pending and marketing and distributing products from the
Patents pending in the 

                 
Territories.

        

      

      
      

      

      A.    The Licensor is prepared to grant to the
Licensee, an exclusive, transferable and non-revocable right and licence to the
Technology within the Territory, subject to the terms and conditions set forth
herein.

      NOW,
THEREFORE, in consideration of the foregoing
and the mutual covenants and agreements contained herein, the receipt and
sufficiency arc acknowledged, the parties hereby agree as
follows:

      

      1.           
DEFINITIONS

       

                     
"Confidential Information"   Means all information (whether in
print, oral, magnetic, optical or electronic form) which is expressly marked as
confidential or which is manifestly of a confidential nature or which is
confirmed in writing to be confidential within thirty (30) day of its
disclosure. It shall include, but shall not be limited to, all information of
the Licensor which relates to:

       

      (a)   the
subject matter of this Agreement;

       

      (b)   the  content
of the Technology, including all directions, instructions, manuals, drawings
and/or processes (whether in tangible form or otherwise) provided to the
Licensee arising out of connection with the use of the Technology 
or any part thereof;

       

      
        
          
          

        

        
          1

          
            

          

        

        
          
          

        

      

      (a)   the
personnel, policies, product plans, designs, costs, finances, marketing plans,
research development or business strategies of the Licensor; and

       

      (a)   the terms
upon which the Technology is being supplied pursuant to this Agreement.

       

      Information shall not be
considered confidential to the extent that it is publicly disclosed through no
fault of the receiving party hereto, either before or after it becomes known to
the receiving party.

      
      

       

      
        	"Documentation"  	Means the operating
      manuals, guides and other support materials provided by the Licensor to
      the Licensee in either print, magnetic, optical or electronic form,
      including any materials which are designed to assist or supplement the
      understanding or application of the Technology.
	 	 
	"Effectivc Date"  	Means the 8th day of
      June 2008.
	 	 
	"End-User"	Means an end-user of
      the Licensed Product that has, before securing access to the Licensed
      Product, entered into an EULA, with the Licensee.
	 	 
	"EULA"	
                Means
      the end-user licence agreement between the Licensee and each end user in
      the Territory which permits the use of the Technology by such end-user and
      which incorporates the provisions set out in Clause
  5.1.7.

              
	 	 
	"Field of Use"	
                Means
      the field of monitoring devices to be used in the health care
      industry.

              
	 	 
	"Implementation
      Date" 	
                Means
      the date upon which the Licensee commences the actual
      fabrication, manufacture and marketing of the products. Such date is
      expected to commence once the second round of financing is completed, some
      120 days after the Effective Date of this
      agreement.

              
	 	 
	"Improvements"  	Means any and all changes, modifications, additions,
      alterations, enhancements, upgrades and development to the
      Technology, but shall not include any part of the Technology or
      Documentation, which remains proprietary to the
  Licensor.

         

        
          
            
            

          

          
            2

            
              

            

          

          
            
            

          

        

        	 	 
	"Intellectual Property
      Rights"	Mean
      any and all vested, contingent or future inventions, innovations,
      discoveries, design rights, model rights, patents, patent applications,
      trade secrets, copyrights, codes, technical information and know-how,
      including but not limited to any methods, techniques, processes,
      discoveries, inventions, innovations, unpatentable processes, technical
      information, specifications, recipes, formulae, designs, plans
      documentation, drawings, data and other technical information, relating to
      the Technology, Documentation and the Licensed Product, registrations of
      and applications to register any of the aforesaid rights, rights in the
      nature of any the aforesaid rights in any country, rights in the nature of
      unfair competition rights and rights to sue for passing off relating to
      the Technology and Documentation and any other proprietary information
      belonging to the Licensor, whether solely, jointly or
      otherwise.
	 	 
	"License" 	Means the licence granted to the Licensee under Clause
    2.
	 	 
	"License
      Fee"  	Means the fees
      payable by the Licensee to the Licensor as set
      out in Clause 3.1.1.
	 	 
	"Licensed
      Product"  	Means any monitoring
      device, in the form prescribed in the Patent
      pending documents, and fabricated using any part of the Technology, and as
      described in Schedule 2.
	 	 
	"Parties"	Means
      the Licensor and the Licensee collectively and "Party" means either the
      Licensee or the Licensor, as the context dictates.
	 	 
	"Revenue"	Means any and all revenues
      received and receivable by the Licensee, including but not limited to
      transaction fees, subscription fees, and all other revenue sources
      attributable to the use of the Technology under this Agreement. For the
      purposes of this
      definition, the Revenue shall be computed prior to any taxes, refund,
      discount, credit or other offset that the Licensee may deduct from the
      Revenue.
	 	 

      

       

      
        
           

        

        
          3

          
            

          

        

        
           

        

      

       

      
        	"Royalty"     	Means the percentage
      of annual Revenue payable by the Licensee
      to the Licensor as calculated in Schedule 3.
	 	 
	"Sale Price"	Means the price
      quoted and charged by the Licensee in direct sales to any party of any
      part of the Licensed Product
	 	 
	"Technology" 	Means the products
      manufactured from the Patents pending as
      described in Schedule I, as the same exists on the Effective Date and to
      be licensed to the Licensee under this Agreement for the Field of
      Use.
	 	 
	"Term"  	Means the licence
      duration as stipulated in Clause 11.1 below.
	 	 
	"Territory"  	Means the
      territories of the world that this License
applies.

      

                                       

      1.2     In
this Agreement, unless contrary intention appears:

       

      (a)      the
clause headings are for case of reference only and shall not be relevant to
interpretation;

       

      (a)      a
reference to a clause number is a reference to its subclauses;

       

      (a)     words
in the singular number include the plural and vice versa;

       

      (a)     words
importing a gender include any other gender;

       

      (a)    
a reference to a person includes bodies corporate and unincorporated
associations and
partnerships;

       

      (a)      a
reference to a schedule or clause is a reference to a schedule or clause of this
Agreement;

       

      (a)      the
recitals to this Agreement do not form part of the Agreement; and

       

      (a)      monetary
references are references to the United States currency.

       

      2.       LICENCE

       

      
        
          
            	
                    2.1  

                  	
                    Subject
      to the Licensee's compliance with the terms and conditions of this
      Agreement, the Licensor hereby grants to the Licensee an exclusive,
      transferable, non-revocable (except for cause) right and licence, to use
      the Technology solely for the purposes
of:

                  

          

        

      

       

      
        
          
            
              
                	
                            2.1.1     
      

                      	
                        to
      fabricate and manufacture products from the
  Patents;

                      

              

            

          

           

          
            
              
              

            

            
              4

              
                

              

            

            
              
              

            

          

           

          
            	
                        2.1.2     
      

                  	
                    to use, have used, make, have made, sell, have
      sold, and lease, sell and/or otherwise transfer copies of the Licensed
      Product on such terms and conditions as described herein and in the
      Schedules annexed hereto, in
      the Field of Use, within the Territory and for the Term
      only.

                  

          

        

      

      
        
          
             

            
              	
                      2.2  

                    	
                      The
      Parties agree and acknowledge that this licence transfers to the Licensee
      the exclusive, transferable, non-revocable interests in the property or
      Intellectual Property Rights to the Technology, Licensed Product and
      Documentation. Titles to the Technology, Licensed Product and
      Documentation and the Intellectual Property Rights of whatever nature
      therein (including any copies, alterations, modifications or amendments
      made hereto) are and shall remain the sole property of the
      Licensor.

                    

            

          

        

         

        
          	
                  2.3  

                	
                  
                    Notwithstanding
      anything in this agreement, and in particular Item 2.2 (above), providing
      all obligations of the Licensee have been met, ownership and title to the
      Technology, Licensed Product and Documentation and the Intellectual
      Properly Rights of whatever nature therein (including any copies,
      alterations, modifications or amendments made hereto) shall transfer to
      the Licensee upon meeting the following
      milestone:

                  

                

        

      

      
         

        •   Meeting
the $1,000,000 revenue mark from evaluation kit sales and/or BT2 watch sales to
prospective distributors.

      

       

      
        	
                2.4  

              	
                The
      parties acknowledge that the technology is patented pending in U.S.A.,
      however the applications for the technology's uses are worldwide.
      Therefore this license applies to all of the countries and territories of
      the world. In the event any patent or patent pending process is or becomes
      in default. Licensee may intervene and correct such
    default.

              

      

       

      
        	
                2.5  

              	
                Should
      the Licensee feel justified in patenting the technology in other countries
      of the world, permission is granted to pursue such action, in whomever
      name is more desirable. Whatever action is taken in this regard, the terms
      and conditions of this license shall
apply.

              

      

       

      
        
          
            	
                    2.6  

                  	
                    All
      rights not expressly granted herein to the Licensee are reserved by the
      Licensor.

                  

          

        

      

        

      3.       FEES
AND GRANT OF EQUITY

       

      
        
          
            	
                    3.1

                  	
                    In
      consideration of the grant of the licence herein, the Licensee agrees to
      pay the Licensor the following
amounts:

                  

          

        

      

       

      
        
          
            
              	
                          3.1.1     
      

                    	
                      A
      non-refundable up-front licence fee of $5,000 being due and payable 120
      days from the date of execution of this Agreement, i.e., on the 8th day of
      June 2008. Such fee shall be payable from the first
      $100,000 raised by the Licensor from investors
      identified by the Parties.

                    

            

          

        

      

       

      
        
          
          

        

        
          5

          
            

          

        

        
          
          

        

      

       

      
        	
                    3.1.2     
      

              	
                A non-refundable royalty advance of $25,000
      being due and payable 210 days from
      the date of execution of this Agreement, i.e., on the 8th day of June
      2008. Such
      fee shall be payable from the next $500,000 raised by the Licensor from
      investors
      identified by the Parties.

              

      

       

      
        	
                        3.13

              	
                The
      fees payable in items 3.1.1 and 3.1.2 shall be considered as advance
      royalty payments
      due in accordance with the royalty scheme set out in Schedule 2 of this
      Agreement
      on a quarterly basis and concurrent with the Licensee's submission of
      sales
      reports pursuant to Clause 5.8, and on the last day the
      Term.

              

      

       

      
        	
                3.2

              	
                All
      payments made to the Licensor shall be in U.S.A. Dollars, without any
      deduction set off or withholding
whatsoever.

              

      

       

      
        	
                3.3

              	
                All
      payments made to the Licensor hereunder shall be exclusive of any sale and
      use tax or any similar tariff, import, duty, fees or assessments
      (including the amount of interest and penalties in connection therewith)
      or governmental charge (collectively know as "Liabilities"). In the event
      such Liabilities are levied upon or chargeable for whatever reason, the
      Licensee shall be responsible for the payment of or reimbursement to the
      Licensor for the payment of such Liabilities (as the case may
      be)

              

      

       

      
        	
                3.4

              	
                Time
      of payment shall be of the essence.

              

      

      
         

        
          
            
              	
                      3.5

                    	
                      In
      the event of any failure to make any payment due to the Licensor in
      accordance with the foregoing clauses, without prejudice to anything else
      in this Agreement and/or any other rights which the Licensor may have at
      law, the Licensor shall have the right
to:

                    

            

             

          

        

      

      
        
          
            
              	
                          3.5.1    
      

                    	
                      forthwith
      suspend or terminate the Licence hereby granted to the Licensee;
      and/or

                    

            

          

        

      

       

      
        	
                    3.5.2    

              	
                
                  provide
      the Licensee an extension of time to complete such payments, at the sole
      discretion of the Licensor

                

              

      

       

      

        	
                    3.5.3    
      

              	
                
                  charge
      the Licensee, in respect of any and all overdue payments, interest at a
      rate of 1% (one per cent) above the base lending rate of the designated
      bank of BT2 International, Inc. per month or part thereof, compounded
      monthly, on the outstanding
balance.

                

              

      

       

      
        
          
            
              	
                      3.6

                    	
                      Upon
      termination of the Licence, the Licensor may repossess any copies of the
      Technology, Documentation and Licensed Product delivered to the Licensee
      or made by the Licensee including such copies of the Licensed Product in
      the control or possession of the Licensee. For such purpose, the Licensee
      or anyone or more of its agents or authorized representatives shall be
      entitled at anytime and without notice to enter upon any premises in which
      the same are or are reasonable believed by the Licensor to be kept, stored
      or used.

                    

            

          

        

      

      
         

        
          
            
              
                	
                        3.7

                      	
                        The
      Parties agree that the Licensor's acceptance of any purported payment of
      Royalty from the Licenses shall not be deemed the Licensor's acceptance of
      the validity and accuracy of any record and document in support thereof.
      For avoidance of doubt, the Licensor
      reverses the right to reject any such record or document as valid or
      accurate subsequent to its acceptance of any purported payment of Royalty
      and in such event, the Licensor shall have the right to recover the
      balance of any sums thereby found due and
  unpaid.

                      

              

            

          

        

      

       

      
        
          
          

        

        
          6

          
            

          

        

        
          
          

        

      

      
        
          
            
              	
                      3.8

                    	
                      The
      parties agree that there will be certain milestones to be achieved during
      the development of the final product and the marketing of this BT2
      product. As each of these milestones is achieved, the Licensee shall grant
      the Licensor common shares in BT2 International, Inc. in accordance with
      Schedule 3.

                    

            

          

        

      

       

      4.       LICENSOR'S
OBLIGATIONS

       

      
        
          
            
              	
                      4.1

                    	
                      
                        The Licensor shall use reasonable endeavours
      to procure the services of all the personnel who made up to development team for the
      Technology. Such services will be available to the Licensee (1) month from the date of
      execution of this Agreement, at such time and place to designated by the Licensor, for the
      sole purpose of assisting in the orientation of such staff of the Licensor in the use and
      operation of the Technology, and for assisting the Licensee in raising the capital monies
      necessary to fabricate, manufacture and market the products from the Technology. The scope of
      such orientation shall be determined solely
      by the
      Licensee.

                      

                    

            

          

        

      

       

      
        	
                4.2  

              	
                The
      Licensee agrees and acknowledges that it shall be solely responsible for
      any and all the transportation and other ancillary costs incurred by its
      selected staff undergoing the orientation in Clause
  4.1.

              

      

       

      
        	
                4.3  

              	
                The
      Licensor shall use reasonable endeavours to procure the services of all
      the personnel who made up the development team for the Technology. Such
      services will be for the purposes of assisting the Licensee with the
      fabrication and manufacturing of the products and to provide other
      technical advice and assistance in any other aspects of the Licensee. Such
      services will be available to the Licensee for a period of 3 years from
      the Implementation Date of this
Agreement.

              

      

       

      
        
          
            
              	
                      4.4

                    	
                      
                        Upon the execution of this Agreement, the
      Licensee hereby confirms that the Licensor has
      effected full delivery of the Technology and Documentation and nothing in
      this Agreement
      shall be construed as requiring the Licensor to prepare or deliver to the
      Licensee
      the Technology, Documentation or any further information, documents or
      data relating
      thereto or engage in any technical studies or research or development or
      any other
      obligation with regards to the use and operation of any part of the
      Technology including
      but not limited to the installation thereof for and on behalf of the
      Licensee.

                      

                    

            

          

        

      

       

      5.       
LICENSEE'S OBLIGATIONS

       

      
        
          
            
              	
                      5.1

                    	
                      The Licensee warrants and undertakes that during the Term or the
      continuance of the licence granted under this
  Agreement:

                    

            

          

        

      

       

      
        
          
          

        

        
          7

          
            

          

        

        
          
          

        

      

       

       

      
        	
                        5.1.1 

              	
                      
                  the
      Technology and Documentation shall be used solely by the Licensee and/or
      any other corporations related or controlled by the Licensee and only for
      the purposes contemplated by Clause 2 of this
      Agreement;

                

              

      

       

      
        	
                           
      5.1.2  

              	
                it
      shall not take any action which may impair the Licensor's ownership and
      exclusive rights to the Intellectual Property
  Rights;

              

      

       

      
        	
                           
      5.1.3  

              	
                it
      shall use its best efforts to raise sufficient financing for the Licensee
      to hire skilled and experienced staff to fabricate, manufacture and then
      market the products from the Technology in order to meet and exceed to the
      target minimums that will pay the Licensor the royalties as
      prescribed;

              

      

       

      
        	
                           
      5.1.4  

              	
                as
      to each employee that is provided access to the Technology and/or the
      Licensed Product, the Licensee shall secure the employee's execution of a
      confidentiality agreement which provides that the employee may access
      and/or use the Technology or the Licensed Product only under terms and
      conditions of the confidentiality agreement which terms shall be
      determined by the Licensee with the approval of the Licensor, and which
      shall include, without limitation, express the acknowledgment by the
      employee of the Licensor's property and rights in the Technology and the
      Licensed Product and express provisions prohibiting the employee
      to:

              

      

       

      
        	
                5.1.4.1  

              	
                sub-license,
      sell, lease, transfer, and distribute the Technology or the Licensed
      Product in any manner whatsoever;

              

      

       

      
        	
                5.1.4.2  

              	
                make,
      manufacture, reproduce or replicate the Technology of the Licensed Product
      in any manner whatsoever;

              

      

       

      
        
          	
                  5.1.4.3  

                	
                  
                    make
      modifications, additions, alterations, enhancements, improvements,
      upgrades or new versions of the Technology or Licensed Product in any
      manner whatsoever;

                  

                

        

      

       

      
        
          	
                             
      5.1..5  

                	
                  
                    it
      shall effect and maintain adequate security measures to the Licensor to
      safeguard the Technology from access and misuse by any unauthorized
      persons (including the copies
thereof).

                  

                

        

      

       

      
        
          	
                  5.2

                	
                  
                    The
      Licensee shall be responsible for obtaining all necessary governmental
      approvals for the development, production, distribution, sale and use of
      any Licensed Product, at the Licensee's expense, including, where
      applicable and without limitation, any safety or feasibility studies. The
      Licensee shall have the sole responsibility of any warning labels,
      packaging and instructions as to the use of the Licensed Product and for
      the quality control for any Licensed
  Product.

                  

                

        

      

       

      
        
          	
                  5.3

                	
                  
                    To
      the extent required by applicable laws, it at all, the Licensee agrees
      that the Licensed Product will be manufactured and/or provided in such
      countries, subject to such consents as may be required or obtained, if at
      all, from the relevant regulatory and/or administration and/or
      governmental
authorities.

                  

                

        

      

       

      
        
          
          

        

        
          8

          
            

          

        

        
          
          

        

      

      
        
          	
                  5.4

                	
                  
                    The
      Licensee shall be responsible for obtaining all third party consents and
      approvals required, including obtaining the right and authority to use,
      distribute, copy, reproduce, broadcast or otherwise disseminate works
      protected by copyright.

                  

                

        

      

      
         

        
          	
                  5.5

                	
                  
                    The
      Licensee shall not use the name, logo or trademarks of the Licensor or any
      variation thereof without the Licensor's prior written
      consent.

                  

                

        

      

       

      
        
          	
                  5.6

                	
                  
                    The
      Licensee agrees to register this Agreement with any foreign governmental
      agency which requires such registrations, and the Licensee shall pay all
      costs and legal fees in connection therewith. In addition, the Licensee
      shall assure that all foreign laws affecting thus Agreement for the sale
      of the Licensed Product arc
satisfied.

                  

                

        

      

      
         

        
          	
                  5.7

                	
                  The Licensee shall maintain complete and accurate records
      of:

                

        

      

       

      
        
          	
                  5.7.1  

                	
                  all
      transactions relating to the Technology and the Licensed
      Product;

                

        

         

        
          	
                  5.7.2  

                	
                  all
      copies made of the Technology and the Licensed
  Product;

                

        

         

        
          	
                  5.7.3  

                	
                  
                    the
      number of sub-licences issued to end-users in respect of the Licensed
      Product; and

                  

                

        

      

      
         

        
          	
                  5.7.4  

                	
                  the
      Revenue received by the Licensee.

                

        

         

        
          
            
              	
                       

                    	
                      
                        which
      the Licensee shall produce to the licensor on request from time to
      time.

                      

                    

            

          

        

         

        
          
            
              	
                      5.8

                    	
                      
                        At
      the end of twelve (12) months from the Effective Date and thereafter on a
      quarterly basis, the Licensee shall submit or caused to be submitted to
      the Licensor accurate and complete sales reports indicating the actual
      sales volume for the relevant quarter and individual sale prices. All
      sales reports shall be accompanied by copies of sale transaction
      documents, including all invoices to the
  End-Users.

                      

                    

            

          

        

        
          
             

            
              	
                      5.9

                    	
                      
                        The
      Licensee agrees that the Licensor shall, at reasonable intervals, have the
      right to appoint an independent auditor to examine the Licensee's relevant
      books and records to verify the Licensee's fulfillment of its obligations
      under this Agreement. The cost of such audit conducted shall be borne by
      the Licensee.

                      

                    

            

             

            
              
                
                  	
                          5.10

                        	
                          
                            The
      Licensee shall at all reasonable times permit the Licensor to check the
      use of the Technology, Licensed Product and Documentation by the Licensee
      and/or verify the accuracy of any and all sales reports furnished by the
      Licensee to the Licensor and for that purpose, the Licensor shall be
      entitled to enter into any of the Licensee's premises upon prior notice
      being given (and the Licensee hereby irrevocably licenses the Licensor,
      its employees and agents to enter such premises for such
      purpose).

                          

                        

                

              

            

             

          

        

      

      6.       WARRANTY
AND LIABILITY

       

      
        
          
            	
                    6.1

                  	
                    The Licensor represents and warrants that is has full corporate
      right and power to enter into this
Agreement.

                  

          

           

        

      

      
        
          
             

          

          
            9

            
              

            

          

          
             

          

        

      

       

      
        
          
            	
                    6.2

                  	
                    
                      The Technology are provided on an "As-Is"
      basis without any warranty of any kind, express
      or implied. The Licensor does not make or give any representation,
      warranty or undertakings
      to the following
  effect:

                    

                  

          

        

      

       

      
        
          
            	
                        6.2.1    
       

                  	
                    that the functions contained in the Technology will meet the
      Licensee's specific requirements or that the functions contained in the
      Technology or the operation of the Technology will be uninterrupted or
      error free or that any defects will be
  corrected;

                  

          

        

      

       

      
        
          
            	
                        6.2.2    

                  	
                    that the Technology will be effective or fit for any purpose or
      that it is supplied by the Licensor free from any defect or error,
      or

                  

          

        

      

       

      
        
          
            	
                        6.2.3    
      

                  	
                    that the use or sale of the Licensed Product or the use of the
      Technology and/or Documentation will not infringe any of the copyright or
      the Intellectual Property Rights or any other rights belonging to or
      alleged to belong to any third
party.

                  

          

        

      

       

      
        
          
            	
                    6.3

                  	
                    
                      The
      express terms of this Agreement are in lieu of all warranties, conditions,
      terms, undertakings and obligations implied by statute, common law,
      custom, trade usage, course of dealing or otherwise, all of which are
      hereby excluded to the fullest extent permitted by
    law.

                    

                  

          

        

      

       

      
        
          
            	
                    6.4

                  	
                    
                      The
      Licensor shall not be liable to the Licensee, End-User or any third party
      for any special, indirect, incidental, punitive, consequential, exemplary
      or any other damages whatsoever (including, without limitation, damages
      for loss of profits or revenues, business interruption, loss of data, loss
      of business information, other pecuniary loss and cost of legal expense)
      in connection with this Agreement and, without limitation, the use or
      performance of the
Technology.

                    

                  

          

        

      

      
        
           

          
            	
                    6.5

                  	
                    
                      The
      total and cumulative liability of the Licensor to the Licensee for any
      claims or damages under this Agreement whether arising out of contract,
      tort or any other cause of action, shall be limited to direct damages and
      shall in no event exceed the sums paid by the Licensee to the Licensor
      under this Agreement in the last twelve (12) months prior to the event
      giving rise to the
claim.

                    

                  

          

        

      

       

      7.       INTELLECTUAL
PROPERTY RIGHTS

       

      
        
          
            	
                    7.1

                  	
                    
                      The
      Licensee shall have the right to apply for registration of any of the
      Intellectual Property Rights anywhere in the world that the Licensor has
      not applied for a Patent, however the Licensee shall at no time challenge
      the validity and the Licensor's ownership of the
    same.

                    

                  

          

        

      

       

      
        
          
            	
                    7.2

                  	
                    
                      Interest
      and title to all Improvements carried out by the Licensee (the "Licensee's
      Improvements"), if any, shall be the subject matter of intellectual
      property and shall vest solely and exclusively in the
      Licensor.

                    

                  

          

        

      

      

        
          
             

          

          
            10

            
              

            

          

          
             

          

        

      

      
        
           

          
            	
                    7.3

                  	
                    
                      Licensee shall report in writing to the
      Licensor the details of any and all Improvements carried
      out by the Licensee and shall produce to the Licensor such written reports
      one (1) month
      after the Effective Date and thereafter on a monthly basis without demand.
      The Licensor
      shall be entitled at any time to be availed of further details of any such
      report furnished,
      including any record or document in support
      thereof

                    

                  

          

        

      

       

                 
OR

       

      
        
          
            	
                    7.4

                  	
                    
                      Notwithstanding anything to the contrary,
      nothing in this Agreement shall be construed as
      according to the Licensee any right whatsoever to customized, adapt, alter
      or make any changes
      to the
Technology.

                    

                  

          

        

      

       

      
        
          
            	
                    7.5

                  	
                    
                      For
      the avoidance of doubt, the Licensee shall not be entitled to, and the
      Licensor shall not be obliged to provide, any improvements, or any
      upgrade, development or improvement to the Technology and/or Licensed
      Product.

                    

                  

          

        

      

       

      
        
          
            	
                    7.6

                  	
                    
                      The
      Parties shall negotiate in good faith and set out in a separate written
      agreement their respective rights and obligations vis-a-vis
      commercialization and protection of the Intellectual Property Rights in
      the Licensee's
Improvements.

                    

                  

          

        

      

       

      8.       CONFIDENTIALITY

       

      
        
          
            	
                    8.1

                  	
                    
                      The parties agree that during the Term of this
      Agreement and after this Agreement expires
      or is terminated (as the case maybe), a party receiving Confidential
      Information of
      the other party will
  continue:

                    

                  

          

        

      

       

      
        
          	
                  8.1.1  

                	
                  to
      maintain in confidence such Confidential Information to the same, extent
      such party maintains its own proprietary aud confidential
      information;

                

        

      

       

      
        	
                8.1.2  

              	
                not
      to disclose such Confidential Information to any third party without prior
      written consent of the other party;
and

              

      

       

      
        	
                8.1.3  

              	
                not
      to use such Confidential Information for any purpose except those
      permitted by this Agreement.

              

      

       

      
        
          	
                  8.2

                	
                  
                    Provided
      that where the Licensor is the party receiving Confidential Information,
      the Licensor may disclose all or part of that Confidential Information to
      its associates on the basis that such associates shall also observe and be
      bound by the provisions of this Agreement. For the purpose of this
      Agreement, the associates of the Licensor shall include the Licensor's
      related corporations (as defined in the Companies
    Act).

                  

                

        

        
          	
                  8.3

                	
                  
                    Notwithstanding
      any other provisions in this Agreement and for the avoidance of doubt, the
      Licensor shall be entitled to disclose to any third parties the fact of
      this Agreement and its ownership of the Intellectual Property Rights and
      such disclosure may be for any purpose
      whatsoever.

                  

                

        

      

      

        
          
             

          

          
            11

            
              

            

          

          
             

          

        

9.   
INDEMNITY

       

      
        
          	
                  9.1   

                	
                  
                    The Licensee shall indemnify and hold the
      Licensor harmless from and against any and all costs, losses, liabilities and expenses
      (including legal costs on a full indemnity basis) in
      connection with or arising out
  of:

                  

                

        

      

       

      
        	
                9.1.1  

              	
                any
      breach of the Licensee's obligations in this Agreement, including without
      limitation, any breach of warranties herein, or any third party claim,
      action or allegation brought about against the Licensor related to the
      Licensee's use or misuse of the Technology, or the Licensed Product or
      Documentation or any Intellectual Property Rights, or any dispute between
      the Licensee and any third party;
or

              

      

       

      
        	
                9.1.2  

              	
                any
      act or omission or default by the Licensee or its agents, employees and
      contractors pursuant to this
Agreement.

              

      

       

      
        
          	
                  9.2   

                	
                  
                    In addition to any other remedies available to
      the Licensor under this Agreement orotherwise, the Parties agree that any
      unauthorized use, alteration, modification, amendment, reproduction, publication,
      disclosure or transfer of the Technology, or the Licensed Product or Documentation or any
      Intellectual Property Rights, will entitle the Licensor
      to any and all available equitable remedies against the
      Licensee.

                  

                

        

      

       

      10.    INFRINGEMENT
ACTIONS

       

      
        	
                10.1  

              	
                If
      any claim is made or threatened against the Licensee by any third party
      that the exercise by the Licensee of any rights granted under this
      Agreement by the Licensor infringes any Intellectual Property Rights of
      any other person, the Licensee shall fully notify the Licensor as soon as
      it becomes aware of the claim or threatened
  claim.

              

      

       

      
        	
                10.2  

              	
                'THe
      Licensor shall be given full control of any proceedings or negotiations in
      connection with the claim and shall be exclusively entitled to appoint and
      instruct legal advisors and counsel in connection with any such
      proceedings or negotiations and to determine the forum for any such
      proceedings.

              

      

       

      
        	
                10.3  

              	
                The
      Licensee shall, at its own costs, give the Licensor all reasonable
      assistance for the purpose of any such proceedings or
      negotiations.

              

      

       

      
        	
                10.4  

              	
                The
      Licensee shall not pay or accept any such claim, or compromise any such
      proceedings without the consent of the
Licensor.

              

      

       

      
        	
                10.5  

              	
                The
      Licensor shall be entitled to require the Licensee to take such steps as
      the Licensor may reasonable require to mitigate or reduce any loss or
      damage.

              

      

       

      
        
          	
                  10.6

                	
                  The
      Licensee shall permit any action to be brought in its name if required by
      law.

                

          
            
               

            

            
              12

              
                

              

            

            
               

            

          

        

         

      

      
        	
                10.7

              	
                The
      Licensor shall have no liability to the Licensee in respect of any claim
      for infringement of any Intellectual Property Rights which is based on the
      use of or any other dealing in any of the Intellectual Property Rights
      otherwise than in accordance with this
  Agreement.

              

      

       

      11.    
TERM AND TERMINATION

       

      
        
          	
                  11.1

                	
                  This
      Agreement shall last for a period of sixteen (20) years from the Effective
      Date.

                

        

      

       

      
        	
                11.2  

              	
                [The
      Parties agree to review the commercial viability of the Licence granted
      under this Agreement at the end of two (2) years from the Effective Date
      and may (but shall not be obliged to) vary, by mutual agreement in
      writing, the terms and conditions herein. Unless varied as aforesaid, this
      Agreement and its terms and conditions shall continue to apply for the
      balance of the Term. ]

              

      

       

      
        
          	
                  11.3

                	
                  This
      Agreement may be terminated:

                

        

      

       

      
        	
                11.3.1  

              	
                without
      cause, by the Licensee giving not less than sixty (60) days written notice
      to the Licensor;

              

      

       

      
        	
                11.3.2  

              	
                forthwith
      by either party if the other commits any breach of any term of this
      Agreement and which (in the case of a breach capable of being remedied) is
      not remedied within fourteen (14) days of a written request to remedy the
      same. Save that a breach for non-payment or under-paymcnt of Royalty shall
      be remedied within seven (30) days.

              

      

       

      
        	
                11.3.3  

              	
                forthwith
      by either party if the other shall convene a meeting of its creditors or
      if a proposal shall be made for a scheme of arrangement or a proposal for
      any other composition scheme or arrangement with (or assignment for the
      benefit of) its creditors or if the other shall be unable to pay its debts
      as they fall due or if a receiver and/or manager or similar officer is
      appointed in respect of all or any part of the business or assets of the
      other party or if a petition is presented or a meeting is convened for the
      purpose of considering a resolution or other steps are taken for the
      winding up of the other party or for the placing of the other party under
      judicial management (otherwise than for the purpose of a solvent scheme of
      amalgamation or reconstruction).

              

      

       

      
        	
                11.4

              	
                Any termination of this Agreement howsoever
      occasioned shall be without prejudice to any
      other rights or remedies a party may be entitled to hereunder or at law
      and shall not affect
      any accrued rights or liabilities of either party nor the coming into or
      continuance in
      force of any provision hereof which is expressly or by implication
      intended to come into
      or continue in force on or after such
      termination.

              

      

      
         

        
          	
                  11.5  

                	
                  Upon
      termination of this Agreement by the Licensor (howsoever
      occasioned):

                

        

      

       

      
        	
                11.5.1  

              	
                the
      Licensee's rights to use the Technology, Licensed Product and
      Documentation and all other rights as set forth in this Agreement shall
      cease with immediate effect; and

              

      

       

      
        
          
          

        

        
          13

          
            

          

        

        
          
          

        

      

      
        	
                11.5.2  

              	
                the
      Licensee shall within fourteen (14) days deliver up, at its own cost and
      expense, to the Licensor all and any copies of the Technology, the
      Licensed Product and Documentation, and procure the erasure or
      obliteration of all storage devices or media used to store, contain, carry
      or record the same, and shall certify in writing to the Licensor that no
      copies thereof have been retained;
and

              

      

       

      
        	
                11.5.3  

              	
                the
      Licensee shall not use, have used, make, have made, sell, have sold and
      lease, sell or otherwise apply any technology (including software, whether
      as source codes or otherwise) which are similar to the Technology except
      through a licence of the Technology to be granted by the Licensor on terms
      and conditions to be agreed in writing between the Licensor and the
      Licensee.

              

      

       

      
        
          	
                  11.6 

                	
                  
                    Upon
      expiration of this agreement, the Licensor's rights to the Technology,
      Licensed Product and Documentation shall revert to the Licensee, (provided
      the minimum annual royalties have been paid) and no further royalties
      shall be payable.

                  

                

        

      

       

      
        	
                11.7

              	
                In
      addition to such provisions which survive the expiration or termination of
      this Agreement by operation of law, the provisions of Clauses 3.6, 3.7,
      5.7, 5.9, 5.10, 6, 7, 8, 9, 10, 11 and 12 shall continue in force in
      accordance with their terms, notwithstanding the expiration or termination
      of this Agreement for any reason.

              

      

       

      12.    
GENERAL PROVISIONS

       

      
         

        
          	
                  12.1 

                	
                  
                    The
      relationship between the Licensor and Licensee is that of independent
      contractors. The Licensor and Licensee are not joint venturers, partners,
      principal and agent, master and servant, employer or employee, and have no
      other relationship other than independent contracting parties. The
      Licensor and Licensee shall have no power to bind or obligate each other
      in any manner, other than as is expressly set forth in this
      Agreement.

                  

                

        

        
           

          
            	
                    12.2

                  	
                    
                      Neither
      this Agreement nor any rights granted hereunder may be assigned or
      transferred by Licensee without the prior written consent of the
      Licensor.

                    

                  

          

          
             

            
              	
                      12.3

                    	
                      
                        This
      Agreement sets forth the entire agreement and understanding between the
      parties as to the subject matter hereof. There shall be no amendments or
      modifications to this Agreement, except by a written document which is
      signed by both parties.

                      

                    

            

             

            
              
                	
                        12.4

                      	
                        
                          The
      headings for each article and section in this Agreement have been inserted
      for 12.1 convenience
      of reference only and are not intended to limit or expand on the meaning
      of (the language contained in the particular article or
      section.

                        

                      

              

            

             

            
              
                
                

              

              
                14

                
                  

                

              

              
                
                

              

            

          

        

      

      
        	
                12.5  

              	
                Should
      anyone or more of the provisions of this Agreement be held invalid or
      unenforceable by a court of competent jurisdiction, it shall be considered
      severed from this Agreement and shall not serve to invalidate the
      remaining provisions thereof. The parties shall make a good faith effort
      to replace any invalid or unenforceable provision with a valid and
      enforceable one such that the objectives contemplated by them when
      entering this Agreement may be
realized.

              

      

       

      
        
          	
                  12.6

                	
                  
                    This
      Agreement shall be construed and enforced in accordance with the laws of
      Nevada.

                  

                

        

      

       

      
        	
                12.7  

              	
                Any and all disputes arising out of or in
      connection with this Agreement including any question regarding its
      existence, validity or termination, shall be referred to arbitration in
      Nevada in accordance with the Rules for the time being in force which
      rules are deemed to be incorporated by reference into this clause. The
      tribunal shall consist of one (1) arbitrator to be appointed pursuant to
      the arbitration Rules. The arbitrator's decision shall be final and
      binding upon the parties and shall provide the sole and exclusive remedies
      of the parties. All judgement upon the award so rendered may be
      entered in any court having jurisdiction or application may be made to
      such court for a judicial acceptance of the award or orders of
      enforcement. The commencement of any arbitration proceedings under this
      Clause shall in no way affect the continual performance of the obligations
      related to the subject matter of such proceedings. All arbitration
      proceedings shall be in the English
  Language.

              

      

       

      
        	
                12.8  

              	
                Any
      delay in enforcing a party's rights under this Agreement or any waiver as
      to a particular default or other matter shall not constitute a waiver of
      such party's rights to the future enforcement of its rights under this
      Agreement, excepting only as to an express written and signed waiver as to
      a particular matter for a particular period of
  time.

              

      

       

      
        	
                12.9  

              	
                Any
      notices required by this Agreement shall be in writing, shall specifically
      refer to this Agreement and shall be sent by registered or certified
      airmail, postage prepaid, or by telefax, telex or cable, charges prepaid
      or by overnight courier, postage prepaid and shall be forwarded to the
      respective addresses set forth below unless subsequently changed by
      written notice to the other party:

                 

                For
      the Licensor:       David
      Bychkov

                                                     7432
      Emerald Drive 

                                                     Manassas,
      Virginia

                 

                 

                For
      the Licensee:      BT2 International,
      Inc.

                                                    Suite
      2067, 1117 Desert Lane, 

                                                    Las
      Vegas NV 89102-0000

                 

                Notice shall be deemed delivered upon the earlier of (i) when
      received, (ii) three (3) days after deposit into the mail, or (iii) the
      date notice is sent via telefax, telex or cable, (iv) the day immediately
      following delivery to overnight courier (except Sunday and
      holidays).

              

      

       

      
        
          
          

        

        
          15

          
            

          

        

        
          
          

        

      

      
        	
                12.10  

              	
                Save
      as provided in Clause 12.11 below, a person who is not a party to this
      Agreement has no right under the Contracts (Rights of Third Parties) Act
      2001 to enforce any terms and conditions of this
  Agreement.

              

      

       

      
        	
                12.11  

              	
                If,
      at any time after the date of this Agreement the functions and operations
      of the Licensor are assigned, merged, transferred into or otherwise forms
      part of another organization (the "New Entity"), such that the New Entity
      takes over the whole or substantially the whole of the Licensor's
      operations, then it is agreed that this Agreement may, at the option of
      the Licensor, be novated to the New Entity which will than assume all of
      the Licensor's rights and obligations hereunder. It is further agreed that
      the Licensor may assign all or any part of its rights hereunder to the New
      Entity or to any Licensor's Affiliate at nominal
      consideration.

              

      

      

      IN
WITNESS WHEREOF this Agreement has been executed as of the day and year set out
below.

       

      For
and on behalf of: 

       

      BT2
International, Inc.

      
        
          	 	 	 
	Signature:	/s/Joseph Batty	 
	Name:	Joseph
      Batty	 
	Designation:	Chief
      Executive Officer	 
	Date:	 	 

        

      

       

      In
the presence of:

       

      Signature:________________________

       

      Name:____________________________

       

      Date:_____________________________

      

      

      
        
          
             

          

          
            16

            
              

            

          

          
             

          

        

      

       

      For and on behalf
of:

       

      David
Bychkov_________________________

       

      
        
          	 	 	 
	Signature:	/s/David Bychkov	 
	Name:	David
      Bychkov	 
	Designation:	Owner,
      Exmocare LLC	 
	Date:	June
      8, 2008	 

        

         

         

      

      
        	In presence of:
    	/s/Nadia Madjid	 
	Name:	Nadia
      Madjid	 
	Date:	June
      8, 2008	 

      

    

     

    
      

      
        
           

        

        
          17

          
            

          

        

         

      

      SCHEDULE 1

       

      Description
of Technology

      

      All
products that are fabricated and manufactured using the designs from the
following patents pending as described below:

       

      Bluetooth-transmitting
biosensor wristwatch to simultaneously detect and continuously monitor heart
rate, heart rate variability, skin conductance, skin temperature, relative
moment and other vital signs.

       

      Biosensor
enhanced steering wheel to simultaneously detect and continuously monitor
electrocardiogram, galvanic skin response, skin temperature and relative
movement.

       

      Biosensor
enhanced turnstile to detect galvanic skin response, skin temperature and
torque.

       

      Biosensor
enhanced PC mouse to detect heart rate, galvanic skin response, skin temperature
and relative movement.

       

      System
to detect human emotions from the above mentioned wristwatch, above mentioned
steering wheel, above mentioned turnstile and above mentioned
mouse.

       

      System
to process physiological, emotional and hardware-related alerts through the
internet, cellular networks and other media from the above mentioned
products.

       

      
        
           

        

        
          18

          
            

          

        

         

      

      SCHEDULE 2

      Royalty Obligations arc in
accordance with the following Royalty Policy:

       

      BT2
INTERNATIONAL, INC.

       

      DIRECTORS'
RESOLUTION 

       

      Business
Model/Royalty Policy

      

      Business Model

      

      BT2
International, Inc. has developed the BT2 watch (hereinafter know as BT2) that
is intended for mass production and sale to mature adults who need assistance
with their daily living and could benefit from the BT2 ability to monitor their
vital signs on a regular basis.

       

      The
Company intends to market the BT2 similar to a cellular phone. The BT2 unit will
be provided to a customer at a "nominal" price, plus a monthly fee to monitor
the results from the unit. Current planning provides for the BT2 to be sold at
approximately $100 per unit and the monthly monitoring fee to be approximately
$30 per month.

       

      The
BT2 will be sold by a network of distributors around the world and will be
monitored by security companies, phone companies, etc. The vital sign results
from the BT2 will be assessed by the computers that receive the signals and the
monitor/computer will determine what type of corrective action may be needed on
a patient by patient basis.

      

      Royalty
Policy

      

      BT2
International, Inc. will split its revenue into 2 categories:

       

      1. BT2
unit sales

      2. Monthly
monitoring revenue

       

      Since
the units are sold at a "nominal" price, there will be little or no profit
derived from these sales. It is the monthly monitoring revenues that will
produce a healthy revenue stream and significant profits. The margins on this
revenue stream will be substantial.

       

      The
$30 per month revenue stream will be divided amongst the distributor, the
monitoring company and BT2 International, Inc. Our current expectations are that
BT2 International, Inc. will receive between $10 and $20 per month for each of these units
sold. Final determination of how this monthly fee will be
allocated will depend on the country and the company that is engaged to monitor
the units.

      
        
           

        

        
          19

          
            

          

        

        
           

        

      

      BT2
International, Inc. intends to place 30% of its revenue (between $10 and S20 per
month for each of these units) from this monthly monitoring fee into a royalty
pool.

      

      Payments
will be made from this royalty pool to the following 3 parties:

       

      1.
Royalty Unit Holders

       

      a.  Royalty
Unit Holders are those people/corporations who have purchased a unit as
an
investment in BT2 International, Inc. 

       

      b.
The Royalty Units will be considered "Non-mature"
until they have been repaid for
2 times the amount of the purchase price 

       

      c. The
Royalty Units will be considered "Mature"
once they have been repaid for 2 times
the amount of the purchase price 

       

      d.
Once the Royalty Units have been repaid for 2 times the amount of the purchase
price
and have "Matured" the formula for determining the amount of the royalty
due
to these Units will change.

       

      2. Exmocare
LLC, et al

       

      a. Exmocare
LLC and David Bychkov are the inventors of BT2

      
         

        b. As part of the
creation of BT2 International, the inventors are due to be paid a  royalty.

      

       

      3.      Shareholders
of BT2 International, Inc.

       

      The
formula for determining the amounts of these payments are as
follows:

       

      •      During the
period that the Royalty Units have not
matured:

       

      
        	
                1.  

              	
                60%
      of the amount placed into the royalty pool shall be paid to the Royalty
      Unit holders

              

      

       

      
        
          	
                  2.  

                	
                  15%
      of the amount placed into the royalty pool shall be paid to Exmocare LLC,
      et al

                

        

      

       

      
        	
                3.  

              	
                25%
      of the amount placed into the royalty pool shall be paid to the
      shareholders of BT2 International,
Inc.

              

      

       

      •      After the
Royalty Units have matured:

       

      
        	
                1.  

              	
                10%
      of the amount placed into the royalty pool shall be paid to the Royalty
      Unit holders

              

      

       

      
        
          	
                  2.  

                	
                  25%
      of the amount placed into the royalty pool shall be paid to Exmocare LLC,
      et al

                

        

      

       

      
        	
                3.  

              	
                65%
      of the amount placed into the royalty pool shall be paid to the
      shareholders of BT2 International,
Inc.

              

      

       

      The
amount of royalties to be placed into the royalty pool shall be calculated
quarterly and shall be paid within 15 days after the end of each
quarter.

      
        
           

        

        
          20

          
            

          

        

         

      
SCHEDULE
3

      

       

      Milestones
and Grant of Equity

      

      The
parlies agree that there will be certain milestones to be achieved during the
development of the final product and the marketing of this BT2 product. As each
of these milestones is achieved, the Licensee shall grant the Licensor common
shares in BT2 International, Inc. as follows:

       

      
        	
                •  

              	
                Raising
      the first $100,000 of equity/royalty units in BT2 International, Inc. -
      grant of 500,000 common shares

              

      

       

      
        	
                •  

              	
                Raising
      the next $500,000 of equity/royalty units in BT2 International, Inc. -
      grant of 500,000 common shares

              

      

       

      
        
          	
                  •  

                	
                  Raising the next $1,000,000 of equity/royalty
      units in BT2 International, Inc. - grant
      of 500,000 common
shares

                

        

      

       

      
        	
                •  

              	
                Raising
      the more than $5,000,000 of equity/royalty units in BT2 International,
      Inc. - grant of 2,500,000 common
shares

              

      

       

      
        	
                •  

              	
                Meeting
      the $200,000 revenue mark from evaluation kit sales to prospective
      distributors - grant of 500,000 common
shares

              

      

       

      
        	
                •  

              	
                Meeting
      the $1,000,000 revenue mark from evaluation kit sales and/or BT2 watch
      sales to prospective distributors - grant of 1,000,000 common
      shares

              

      

       

      
        	
                •  

              	
                BT2
      International, Inc. going public or merging with a public company - grant
      of 5,000,000 common shares

              

      

      
         

        
          	
                  •  

                	
                  Transfer
      of title of ownership as per Clause 2.3 - grant of 500,000
      common shares

                

        

      
        
          
          

        

        
          21exmo_ex102.htm

     

    Exhibit
10.2

     

    COMMON
STOCK PURCHASE AGREEMENT

     

    Private
and Confidential

     

    THIS
COMMON STOCK PURCHASE AGREEMENT, (the "Agreement") made as of the last executed
date below (the Effective Date"), by and among BT2 International, Inc. an entity
with a principle address of 1117 Desert Lane, Suite 2067, Las Vegas, NV 89102
(the "Buyer") and Belmont Partners, LLC a Virginia limited liability company
with a principal address of 360 Main Street, Washington Virginia 22747
("Seller"), and Clopton House Corporation a FormlO vehicle organized in the
state of Delaware (the "Company") and Escrow, LLC ("Escrow Agent") (Buyer,
Seller and Company each a "Party" and collectively the
"Parties").

     

    W
I T N E S S E T H:

    

     

    WHEREAS, the Seller owns a majority of the
issued and outstanding capital stock of the Company; and

     

    WHEREAS, the Buyer wishes to purchase a control
block of stock consisting of one hundred thousand (100,000) shares representing
one hundred percent of the issued and outstanding capital stock of the Company
(the "Stock");

     

    NOW, THEREFORE, in consideration of the mutual
promises, covenants, and representations contained herein, and subject to the
terms and conditions hereof, the Parties agree as follows:

     

    1.            
Agreement
to Purchase and Sell. Seller will sell to Buyer and Buyer agrees
to purchase the Stock
in exchange for:

     

    a)   fifty
thousand U.S. dollars ($50,000.00) together with two hundred U.S. dollars
representing Buyer's half of the Escrow Fees (the "Purchase Price"), to be paid
to Seller according to the terms and conditions set forth in Section 3 herein;
and,

     

    b)   three
percent (3%) of the issued and outstanding common stock of the Company according
to the terms and conditions set forth in Section 3(e) herein (the
"Position").

    

    2.   Closing.
On or about five (5) business days from the Effective Date (the "Closing")
the

     

    Parties
shall perform, in order:

     

    a)   Buyer
shall deliver to Seller a copy of this Agreement executed by Buyer;

     

    b)    Seller shall
deliver a fully executed copy of this Agreement to Buyer;

     

    c)    The Escrowed
Funds (defined in Section 3(a) herein) shall be released to Seller;

     

    
    

    
      
        
        

      

      
        1

        
          

        

      

      
        
        

      

       

      d)    Seller shall
cause the board of directors of the Company to execute a resolution approving
the terms of this Agreement through which all current Director's of the
Company
resign and Buyer, or Buyer's designee, is appointed as a Director of the
Company
(the "Appointment");

       

      e)   Buyer shall deliver
to Seller a resolution of the board of directors of the Company and
Irrevocable Transfer Agent Instructions to effectuate performance of Sections
1(b) and 3(e)
of this Agreement (the "Board Resolution");

       

      f)   Buyer
shall deliver to Seller a resolution of the majority shareholders of the Company
to effectuate performance of Section 1(b) and 3(e) of this Agreement (the
"Shareholder Resolution");

       

      g)   Seller
shall deliver to Buyer the Appointment;

    

     

     

    h)    Seller shall
deliver to Buyer, to the extent reasonably available to Seller, and after
the full
performance of Section 3(a), true and correct copies of the Company's business,
financial
and corporate records including but not limited to: correspondence files, bank
statements,
checkbooks, minutes of shareholder and directors meetings, financial
statements,
shareholder listings, stock transfer records, agreements and contracts;
and,

     

    i)    Seller shall
deliver to Buyer, as soon as practicable after the full performance of
Sections
2(a) through 2(g) herein, the stock certificates) evidencing the
Stock

     

    3.   Payment
Terms.

     

     

    a)    Buyer shall
place a deposit of ten thousand U.S. Dollars ($10,000.00) into an escrow account
with Escrow, LLC (the "Escrow Agent") on behalf of the Seller (the
'Deposit") on the Closing date. The balance of the Purchase Price (the
"Balance") shall be due and payable on the following dates (each a "Maturity
Date", collectively the "Maturity Dates"):

     

    (i)         
Payment in the amount of five thousand U.S. dollars ($5,000.00) on or
before
forty five (45) days from the Effective Date;

     

    (ii)        
Payment in the amount of five thousand U.S. dollars ($5,000.00) on or
before
seventy five (75) days from the Effective Date;

     

    (iii)       
Payment in the amount of five thousand U.S. dollars ($5,000.00) on or
before
one hundred five (105) days from the Effective Date;

     

    (iv)       
Payment in the amount of five thousand U.S. dollars ($5,000.00) on or
before
one hundred thirty five (135) days from the Effective Date;

     

    
      
        
        

      

      
        2

        
          

        

      

      
        
        

      

    

            

    (v)        
Payment in the amount of five thousand U.S. dollars ($5,000.00) on or
before
one hundred sixty five (165) days from the Effective Date;

     

    (vi)       
Payment in the amount of fifteen thousand U.S. dollars ($15,000.00) on or
before
two hundred fifty five (255) days from the Effective Date.

     

    b)    Wire transfer
of all payments hereunder shall be made on or before each payment's respective
Maturity Date by wire transfer of immediately available funds to Seller's
account as follows:

            

    
      	Bank Name:	 	
              Rappahannock
      National Bank

            
	 	 	7 Bank
  Road
	 	 	Washington, Virginia
      22747 
	Account
    Name:	 	Belmont Partners,
      LLC
	Account
      Number:	 	1089129
	Routing
      Number:	 	
              051402974

            

    

     

    c)   The
Purchase Price may be prepaid in whole or in part at any time, at the option of
Buyer without premium or penalty.

     

    d)   If at
anytime during the term of this Agreement Buyer shall fail to pay a payment on
or before the payment's respective Maturity Date, all outstanding principal, any
accrued and unpaid interest and any other amounts due hereunder shall bear an
interest rate of eighteen percent (18%) per annum from the day such interest is
due hereunder through and including the final day of payment of all outstanding
principal, accrued interest and other amounts due hereunder. The payments of
interest hereunder shall not be required to the extent that receipt of any such
interest by the Seller would be contrary to provisions of law applicable to the
Seller limiting the maximum rate of interest that may be charged or collected by
the Seller.

     

    e)    Stock
Position.

     

    (i)            In
consideration of the benefits provided to the Company hereby, Company
shall issue and deliver to Seller, such fully paid, non-assessable restricted
shares of the Company's common stock equal to a three percent (3%) post
Vend-in of I.P. ownership interest in the Company (the Position"). The
Position
shall be based on the capital structure of the Company post Vend-in of
I.P.
(taking into account any and all shares issued relating to the Vend-in of I.P.,
initial
contracts, and initial acquisition of any assets), post reverse stock split (if
any),
post initial financing, and after any other initial issuance of stock (including
issuance
to the Company's directors and/or officers). Buyer shall take all steps
necessary
to fully effectuate the provisions of this Section 3.

     

    (ii)           Certificate
evidencing the Position shall be issued and delivered to the Seller
immediately following the actions anticipated by Section 3(e)(i) herein
(the "Actions"),
but in no case later than eleven (11) months following the Effective Date
hereof. In the event that all Actions have not been completed by the eleventh
month anniversary of this Agreement, Seller shall transfer to Buyer shares
comprising the Position on that date and shall issue additional shares as
necessary following completion of the Actions.

     

     

    
      
        
        

      

      
        3

        
          

        

      

      
        
        

      

    

     

    (iii)           The
Shareholder Resolution whereby the majority of the shareholders of the
Company agree to the issuance of the Position.

     

    (iv)           The
effective date of all Shares transferred pursuant to this Section 3 shall
be the
Effective Date of this Agreement and shall be memorialized on the face of
the
certificates evidencing such shares.

     

    f)   The
Parties acknowledge and agree that the Position shall be newly issued,
restricted common shares of the Company. Buyer agrees for himself and on behalf
of the Company to accept as valid any legal opinion of Seller's counsel
regarding the removal of restrictions from the Position. In the event that, in
one year from the date of the execution of this Agreement, the Position can not
be sold in accordance with Rule 144 of the Securities Act of 1933, the Seller
shall have demand registration rights on such Position at such time. In the
event that Buyer does not provide the removal of restrictions from the shares
comprising the Position in accordance with Rule 144, does not recognize any
opinion of Seller's counsel regarding the removal of such restrictions, or does
not register such shares, the Company and the Buyer, jointly and severally,
shall pay to Seller liquidated damages in the amount of the bid price per share
as of the one year anniversary of this Agreement (as reported by the national
market on which the shares trade) multiplied by the number of shares in the
Position. The Parties agree that the liquidated damages hereunder are not a
penalty.

     

    g)    In
consideration of the benefits provided to the Company hereby, Company and Buyer
agree to be jointly and severally liable for all amounts due hereunder and all
other obligations of this Stock Purchase Agreement.

     

    4.   Post
Closing Items. Seller agrees to assist Buyer with filing an amendment to the
Company's Articles of Incorporation to change the Company's name and decrease
the authorized shares with the state
of Delaware and possibly re-domiciling the Company to the State of
Nevada.

     

    5.   Default. The
following conditions or events shall constitute events of default ( Event(s) of
"Default"):

     

    a)   if the
Buyer shall default in the performance of or compliance with any term contained
in this Agreement;

     

    b)   if the
Buyer shall be in breach or otherwise default in the performance of, or
compliance with, any other term contained herein and such breach or default is
not remedied within three (3) days of either:

     

    (i)           an
officer of the Buyer obtaining knowledge of such default;

     

    (ii)           Buyer's
Notification of such default; such notification shall be effective upon the
mailing of such Notification to Buyer's last address;

     

    c)   if any
representation or warranty made in writing by or on behalf of the Buyer herein
or in any instrument furnished in compliance with or in reference hereto or
otherwise in connection with the transactions contemplated hereby shall prove to
have been false or incorrect in any material respect on the date as of which
made;

     

    d)   if the
Buyer or any Subsidiary shall be in default (as principal or as guarantor or
other surety) in the payment of any principal of or premium or interest on any
indebtedness with a principal amount in excess of fifty thousand dollars
($50,000.00) (other than this Agreement) or in the performance of or compliance
with my
term of any evidence of any such indebtedness or of any mortgage,
indenture or other agreement relating thereto the effect of which is to cause
such indebtedness to become due and payable before its stated maturity or before
its regularly scheduled dates of payment, and such default, event or condition
shall continue for more than the period of grace, if any, specified therein and
shall not have been waived pursuant thereto;

     

    e)    if the Buyer
or any Subsidiary shall:

     

    (i)    be generally
not paying its debts as they become due;

     

    (ii)   file, or consent by
answer or otherwise to the filing against it of, a petition for
relief or reorganization or arrangement or any other petition in bankruptcy, for
liquidation
or to take advantage of any bankruptcy or insolvency law of any jurisdiction;

     

    (iii)         
make an assignment for the benefit of its creditors;

     

    (iv)         consent
to the appointment of a custodian, receiver, trustee or other officer
with
similar powers with respect to it or with respect to any substantial part of its
property;

     

    (v)   be adjudicated an
insolvent or be liquidated; or

     

    (vi)         
take corporate action for the purpose of any of the foregoing;

     

    f)    if a court or
governmental authority of competent jurisdiction shall enter an order
appointing,
without consent by the Buyer or any Subsidiary, a custodian, receiver, trustee
or other
officer with similar powers with respect to it or with respect to any
substantial part of
its property, or constituting an order for relief or approving a petition for
relief or reorganization
or any other petition in bankruptcy or for liquidation or to take advantage of
any bankruptcy or insolvency law of any jurisdiction, or ordering the
dissolution, winding-up or liquidation of the Buyer or any Subsidiary, or if any
such petition shall be filed against the Buyer of any Subsidiary and such
petition shall not be dismissed within thirty (30) days; or,

     

    
      
        
        

      

      
        4

        
          

        

      

      
        
        

      

       

      g)    if a final
judgment which, with other outstanding final judgments against the Buyer and the
Subsidiaries, exceeds fifty thousand dollars ($50,000.00) shall be entered
against the Buyer or any Subsidiary and if, within sixty (60) days after entry
thereof, such judgment shall not have been discharged or execution thereof
stayed pending appeal, or if, within sixty (60) days after the expiration of any
such stay, such judgment shall not have been discharged.

    

    

    6.   Remedies on
Default.

     

    a)   Upon the
occurrence of any Event of Default, the Seller may proceed to protect and
enforce its rights by suit in equity, action at law and/or other appropriate
proceeding either for specific performance of any covenant, provision or
condition contained in this Agreement, or in aid of the exercise of any power
granted in this Agreement, and (unless there shall have occurred an Event of
Default under Section 6(d) or 6(e), in which case the unpaid balance due
hereunder shall automatically become due andnasjahla) may at its sole option and
with no further notice to the Buyer declare all or any part of the unpaid
principal amount of the Agreement then outstanding to be forthwith due and
payable, and thereupon such unpaid principal amount or part thereof, together
with interest accrued thereon and all other sums, if any, payable under this
Agreement shall become so due and payable without presentation, presentment,
protest or further demand or notice of any kind, all of which are hereby
expressly waived, and the Seller may proceed to enforce payment of such amount
or part thereof in such manner as Seller may elect.

     

    b) Annulment
of Defaults. An Event of Default shall not be deemed to be in existence or to
have occurred for any purpose of this Agreement until the expiration of any and
all grace periods under this Agreement or if the Seller shall have waived such
event in writing or stated in writing that such event has been cured to its
reasonable satisfaction. No waiver or statement of satisfactory cure pursuant to
this Section 7(b) shall extend to or affect any subsequent or other Event of
Default not specifically identified in such waiver or statement of satisfactory
cure or impair any other rights of the Seller herein

    

    7.   Transfer
Agent,

     

    a)    Until such
time as the Purchase Price secured by this Agreement is fully satisfied, and the
terms and conditions of Section 3(e) herein are fully performed, Buyer agrees
that Pacific Stock Transfer, LLC (the "Transfer Agent") shall act as the
Company's sole transfer agency, and Transfer Agent shall have full power and
authority to act on behalf of the Company in connection with the issuance,
transfer, exchange and replacement of all of the Company's stock
certificates.

     

    
      
        
        

      

      
        5

        
          

        

      

      
        
        

      

    

     

    8.   Collections. Should
the indebtedness represented by this Agreement or any part thereof be collected
at law or in equity, or in bankruptcy, receivership or any other court
proceedings (whether at the trial or appellate level), or should any amount due
under this Agreement be placed in the hands of attorneys for collection upon
default, Buyer agrees to pay, in addition to the principal, premium and interest
due and payable hereon, all costs of collection, including reasonable attorney's
fees and expenses.

     

    9.   Representations and
Warranties of Seller. Seller hereby represents and warrants, for a period
of twelve (12) months from the Effective Date, to Buyer that the statements in
the following paragraphs of this Section 11 are all true and complete as of the
date hereof:

     

    a)   Title to
Stock. Seller is the record and beneficial owner and has sole managerial and
dispositive authority with respect to the Stock and has not granted any person a
proxy that has not expired or been validly withdrawn. The sale and delivery
of the Stock to
Buyer pursuant to this Agreement will vest in Buyer the legal and valid title to
the Stock, free and clear of all liens, security interests, adverse claims or
other encumbrances of any character whatsoever ("Encumbrances") (other than
Encumbrances created by Buyer and restrictions on resales of the Stock
under applicable securities laws).

     

    b)   Liabilities
of the Company. Seller makes no representation as to the existence or
non-existence of liabilities of the Company except as explicitly stated in this
Agreement. Buyer is solely responsible for conducting its own due diligence with
respect to the Company and its liabilities and for gathering enough information
upon which to base an investment decision in the Stock Buyer acknowledges
that:

     

    (i)           Seller
has made no representations with respect to the Company or its status
except as explicitly stated in this Agreement; and,

     

    (ii)           the
Company is being sold "as is".

     

    c)    Full Power
and Authority. Seller represents that it has full power and authority to
enter
into this Agreement.

     

    10.           Representations and
Warranties of Buyer. Buyer hereby represents and warrants to Seller
that the statements in the following paragraphs of this Section 12 are all true
and complete as of the
date hereof:

     

    a)    Affidavit of
Source of Funds. Prior to each transfer to seller or each deposit into escrow,
Buyer shall execute an Affidavit of Source of Funds, to the satisfaction of
Seller, which attests that the funds to be transferred are not the proceeds of
nor are intended for or being transferred in the furtherance of any illegal
activity or activity prohibited by federal or state laws. Such activity may
include, but is not limited to: tax evasion; financial misconduct; environmental
crimes; activity involving drugs and other controlled substances;
counterfeiting; espionage; kidnapping; smuggling; copyright infringement; entry
of goods into the United States by means of false statements; terrorism;
terrorist financing or other material support of terrorists or terrorism; arms
dealing; bank fraud; wire fraud; mail fraud; concealment of assets or any effort
by conspiracy or otherwise to defeat, defraud or otherwise evade, any party or
the Court in a bankruptcy proceeding, a receiver, a custodian, a trustee, a
marshal, or any other officer of the court or government or regulatory official;
bribery or any violation of the Foreign Corrupt Practices Act; trading with
enemies of the United States; forgery; or fraud of any kind. Buyer further
warrants that all transfers of monies will be in accordance with the Money
Laundering Control Act of 1986 as amended.

     

    
      
        
        

      

      
        6

        
          

        

      

      
        
        

      

       

      b)   Exempt
Transaction. Buyer understands that the offering and sale of the Stock is
intended to be exempt from registration under the Securities Act of 1933, as
amended (the "Act") and exempt from registration or qualification under any
state law.

       

      c)   Full
Power and Authority. Buyer represents that it has full power and authority to
enter into this Agreement.

       

      d)   Stock. The Stock to
be purchased by Buyer hereunder will be acquired for investment
for Buyer's own account, not as a nominee or agent, and not with a view to
the
public resale or distribution thereof and Buyer has no present intention of
selling, granting
any participation in, or otherwise distributing the same.

       

      e)   Information
Concerning the Company. Buyer has conducted its own due diligence with respect
to the Company and its liabilities and believes it has enough information upon
which to base an investment decision in the Stock. Buyer acknowledges that
Seller has made no representations with respect to the Company, its status, or
the existence or non-existence of liabilities in the Company except as
explicitly stated in this Agreement Buyer is taking the Company "as is" and
acknowledges and assumes all liabilities of the Company.

       

      f)   Investment
Experience. The Buyer understands that purchase of the Stock involves
substantial risk. The Buyer;

       

      (i)           has
experience as a purchaser in securities of companies in the development
stage and acknowledges that he can bear the economic risk of Buyer's
investment in the Stock; and,

       

      (ii)           has
such knowledge and experience in financial, tax, and business matters
so as to
enable Buyer to evaluate the merits and risks of an investment in the
Stock, to
protect Buyer's own interests in connection with the investment and to
make an
informed investment decision with respect thereto.

    

     

    g)   No Oral
Representations. No oral or written representations have been made other
than or in addition to those stated in this Agreement. Buyer is not relying on
any oral
statements made by Seller, Seller's representatives, employee's or affiliates in
purchasing the Stock. 

     

    
      
        
        

      

      
        7

        
          

        

      

      
        
        

      

    

     

    h)   Restricted
Securities. Buyer understands that the Stock is characterized as "restricted
securities" under the Act inasmuch as they were acquired from the Company
in a
transaction not involving a public offering.

     

    i)    Opinion
Necessary. Buyer acknowledges that if any transfer of the Stock is proposed
to be made in reliance upon an exemption under the Act, the Company may
require
an opinion of counsel satisfactory to the Company that such transfer may be made
pursuant
to an applicable exemption under the Act. Buyer acknowledges that a restrictive
legend
appears on the Stock and must remain on the Stock until such time as it may be
removed
under the Act.

     

    j)
Shareholder Value, Buyer represents that Buyer intends to implement a business
plan designed to return value to the shareholders of the Company.

     

    k)   Compliance. Buyer
shall comply with all applicable securities laws, rules and regulations
regarding this Agreement, the Vend-in of I.P. and all related transactions,
including but not limited to filing any forms required by the U.S. Securities
and Exchange Commission.

     

    11.   Covenant Not to Sue;
Indemnification.

     

    a)   In
consideration of this Agreement and the consideration to Buyer and Company
granted herein, Buyer and Company covenant and agree, for themselves and for
their agents, employees, legal representatives, heirs, executors or assigns (the
"Buyer Covenantors"), to refrain from making, directly or indirectly, any claim
or demand, or to commence, facilitate commencement or cause to be prosecuted any
action in law or equity against Seller, its members, officers, directors,
agents, employees, attorneys, accountants, consultants subsidiaries, successors,
affiliates and assigns (selectively the "Seller Covenantees"), on account of any
damages, real or imagined, known or unknown, which Buyer Covenantors ever had,
has or which may hereafter arise with respect to any and all disputes,
differences, controversies or claims arising out of or relating to this
Agreement and the transactions contemplated hereby, including but not limited to
any question regarding the existence, content, validity or termination of this
Agreement. The terms and conditions of this Section 13(a) shall be a complete
defense to any action or proceeding that may be brought or instituted by Buyer
Covenantors against the Seller Covenantees, and shall forever be a complete bar
to the commencement or prosecution of any action or proceeding with regard to
this Agreement by Buyer Covenantors against the Seller Covenantees.

     

    b)   Indemnification.
Buyer Covenantors shall indemnify and hold harmless the Seller Covenantees from
and against any and all losses, damages, expenses and liabilities (collectively
"Liabilities") or actions, investigations, inquiries, arbitrations, claims or
other proceedings in respect thereof, including enforcement of this Agreement
(collectively "Actions") (Liabilities and Actions are herein collectively
referred to as "Losses"). Losses include, but are not limited to all reasonable
legal fees, court costs and other expenses incurred in connection with
investigating, preparing, defending, paying, settling or compromising any suit
in law or equity arising out of this Agreement or for any breach of this
Agreement notwithstanding the absence of a final determination as to a Buyer's
obligation to reimburse any of Seller Covenantees for such Losses and the
possibility that such payments might later be held to have been
improper.

     

    
      
        
        

      

      
        8

        
          

        

      

      
        
        

      

    

    
       

      12.   Governing Law. This
Agreement shall be governed by and construed in accordance with the laws of the
Commonwealth of Virginia, U.S.A. without giving effect to any other choice or
conflict of law provision that would cause the application of the laws of any
other jurisdiction other than the Commonwealth of Virginia.

    

     

    13.   Vend-in of I.P. and Exchange
of Stock. Buyer shall as soon as practicable, and in no case later than
one hundred & twenty (120) days from the Closing, effect a Vend-in of I.P.
(the "Vend-in of I.P."). Upon Vend-in of I.P., the Company shall succeed to and
shall possess all the assets, properties, rights, privileges, powers,
franchises, immunities and purposes, and be subject to all the debts,
liabilities, obligations, restrictions and duties of the Sub.

     

    14.   Term / Survival. The
terms of this Agreement shall be effective as of the Effective Date, and
continue until such time as the payment of the Purchase Price and all other
amounts due hereunder are fully satisfied, however; the terms, conditions, and
obligations of Sections 9, 13, 14 and 27 hereof shall survive the termination of
this Agreement.

     

    15.   Successors and
Assigns. The terms and conditions of this Agreement shall inure to the
benefit of and be binding upon the respective successors and assigns of the
parties, except that Buyer may not assign or transfer any of its rights or
obligations under this Agreement.

     

    16   Counterparts. This
Agreement may be executed in two or more counterparts, each of which shall be
deemed an original, but all of which together shall constitute one and the same
agreement. A telefaxed copy of this Agreement shall be deemed an
original.

     

    17.   Headings. The
headings used in this Agreement are for convenience of reference only and shall
not be deemed to limit, characterize or in any way affect the interpretation of
any provision of this Agreement.

     

    18.   Costs, Expenses. Each
party hereto shall bear its own costs in connection with the preparation,
execution and delivery of this Agreement.

     

    19.   Modifications and
Waivers. No change, modification or waiver of any provision of this
Agreement shall be valid or binding unless it is in writing, dated subsequent to
the Effective Date of this Agreement, and signed by both the Buyer and Seller.
No waiver of any breach, term, condition or remedy of this Agreement by any
party shall constitute a subsequent waiver of the same or any other breach,
term, condition or remedy. All remedies, either under this agreement, by law, or
otherwise afforded the Buyer shall be cumulative and not
alternative.

     

    20.   Severability. If one
or more provisions of this Agreement are held to be unenforceable under
applicable law, such provision(s) shall be excluded from this Agreement and the
balance of the Agreement shall be interpreted as if such provision(s) were so
excluded and shall be enforceable in accordance with its terms.

     

    21.   Termination. Buyer or
Seller may, upon written notice to the other party, terminate this Agreement
upon their own discretion prior to any funds being released from escrow. Upon
the release of any funds from escrow, this termination clause is null and
void.

     

    22.   Entire Agreement.
This Agreement constitutes the entire agreement and understanding of the parties
with respect to the subject matter hereof and supersedes any and all prior
negotiations, correspondence, agreements, understandings duties or obligations
between the parties with respect to the subject matter hereof.

     

    23.   Further Assurances.
From and after the date of this Agreement, upon the request of the Buyer or
Seller, Buyer and Seller shall execute and deliver such instruments, documents
or other writings as may be reasonably necessary or desirable to confirm and
carry out and to effectuate fully the intent and purposes of this
Agreement.

     

    24.   Notices. All notices
or other communications required or permitted by this Agreement shall be in
writing and shall be deemed to have been duly received:

     

    a)   if given
by telecopier, when transmitted and the appropriate telephonic confirmation
received if transmitted on a business day and during normal business hours of
the recipient, and otherwise on the next business day following
transmission,

     

    b)   if given
by certified or registered mail, return receipt requested, postage prepaid,
three business days after being deposited in the U.S. mails and

     

    c)   if given
by courier or other means, when received or personally delivered, and, in any
such case, addressed as indicated herein, or to such other addresses as may be
specified by any such Person to the other Person pursuant to notice given by
such Person in accordance with the provisions of this Section 26.

    

    25.   Insider Trading.
Seller and Buyer hereby certify that they have not themselves, nor through any
third parties, purchased nor caused to be purchased in the public marketplace
any publicly traded shares of the Company. Seller and Buyer further certify they
have not communicated the nature of the transactions contemplated by the
Agreement, are not aware of any disclosure of non public information concerning
said transactions, and are not a party to any insider trading of Company
shares.

     

    
      
        
        

      

      
        9

        
          

        

      

      
        
        

      

    

     

    26.   Binding Arbitration.
In the event of any dispute, claim, question, or disagreement arising from or
relating to this agreement or the breach thereof the Parties hereto shall use
their best efforts to settle the dispute, claim question, or disagreement. To
this effect, they shall consult and negotiate with each
other in good faith and, recognizing their mutual interests, attempt to reach a
just and equitable solution satisfactory to both parties. If they do not reach
such a solution within a period of sixty (60) days, then, upon notice by either
party to the other, all disputes, claims, questions, or disagreements shall be
settled by arbitration administered by the American Arbitration Association in
accordance;, with its Commercial Arbitration Rules including the Optional Rules
for Emergency Measures of Protection, and judgment on any award rendered by the
arbitrators) may be entered in any court having jurisdiction
thereof

     

     

    [Balance
of Page Intentionally Left Blank]

    [Signature
Page Follows]

     

     

    
      
        
        

      

      
        10

        
          

        

      

      
        
        

      

    

     

    In Witness
Whereof, the Parties hereto have executed this Agreement as of the last
date written
below.

     

          SELLER                      BUYER

     

    

     

    
      
        
        

      

      
        11

        
          

        

      

      
        
        

      

    

     

    EXHIBIT
1

    

    THIS AGREEMENT (the
"Agreement") is made the 15th day of December 2008.

    

    Between:

    
       

      (1)   David Bvchkov, founder and inventor of the BT2
technology, an individual whose address is at 7432 Emerald Drive,
Manassas Virginia (hereinafter called "the Licensor") of the first
part;

     

    
    

    And

    
       

      (2)   BT2
International, Inc., a company incorporated in Nevada whose registered
office is at Suite 2067, 1117 Desert Lane, Las Vegas NV 89102-0000 (hereinafter
called "the Licensee") of the second part.

     

    
    

    WHEREAS:

    
       

      A.    The Licensor
and Licensee have completed and signed a Technology License Agreement on the
8th day
of June 2008.

    B.    The License
requires certain conditions and/or events to be met by various
dates.

    

    C.   After
working together on the project, the Licensor and Licensee have mutually 
found
these conditions and/or events and dates need to be
amended.

    
    

     

    
    

    D.   The
License granted to the Licensee, is an exclusive, transferable and non- revocable
right and licence to the Technology within the Territory, subject to the terms and
conditions set forth therein.

    
    

     

    
    

    E.   The
Licensee has now purchased a new Delaware corporation (Clopton House  Corp. to
be renamed Exmovere, Inc,) that is prepared to become a public company,
and both parties wish to transfer certain rights and obligations from the License
Agreement to this new Delaware corporation.

    
    

     

    NOW, THEREFORE, in consideration of the
foregoing and the mutual covenants and agreements contained herein, the receipt
and sufficiency are acknowledged, the parties hereby agree as
follows:

    

    All terms
and conditions of the original Technology License Agreement (copy attached)
shall be transferred, with the following amendments/exceptions:

     

    
      
        
        

      

      
        12

        
          

        

      

      
        
        

      

    

     

    Article
1       Definitions

    

           "Field of
Use" shall be amended by adding: 

           " - except for
use in the field of diabetes. Rights for such use in the field of diabetes shall
remain with BT2 International Inc."

    

    Article
3        Fees and Grant of
Equity

    

    This
section will be deleted and replaced with the following:

     

    Exmovere
Inc. shall adopt a Royalty Policy similar to that described in Schedule 2 of the
Technology License Agreement. However, Exmovere's policy shall require the
Company to allocate 5% of Category 1 revenues (BT2
sales or
other product sales) and 10% of Category 2 revenues (Monthly monitoring revenue
& revenue from the sale of services).

     

    Such
royalty shall be placed into a Royalty Pool. Payments from this royalty pool
shall be made on a quarterly basis, within 15 days after the end of the quarter,
as follows:

     

    20 % of
the pool shall be paid to BT2 International Inc. 80% of the pool shall be paid
to Exmocare LLC, et al

     

    In the
event a financing is obtained that requires dilution of the payments from this
royalty pool, the parties shall dilute on a pro rata basis.

     

    Schedule
2    Directors' Resolution - Royalty Policy

     

    Deleted
and replaced with the above. 

     

    Schedule
3    Milestones and Grant of Equity

     

    Deleted
and replaced with the following:

     

    Exmovere
Inc. shall issue 15,003,000 common shares for the transferred license
rights.

     

    Such
common shares shall be issued as follows:

     

    BT2
International
Inc.                                            
  2,910,000 shares

    Exmocare,
et
al                                                        
 11,640,000 shares

    Belmont
Partners
Inc                                               
    453,000 shares

    
      
         

      

      
        13

        
          

        

      

      
         

      

    

    IN WITNESS WHEREOF this Agreement has been
executed as of the day and year set out below.

     

    For and
on behalf of: 

     

    BT2
International, Inc.

     

    

     

    
      
         

      

      
        14

        
          

        

      

      
         

      

    

     

    EXHIBIT
2

    UNANIMOUS
WRITTEN CONSENT 

    OF
THE BOARD OF DIRECTORS 

    IN
LIEU OF A SPECIAL MEETING

    

     

    In lieu
of a Special Meeting of the Board of Directors of Clopton House Corporation a
corporation organized in the State of Delaware (the "Company"), the
undersigned, being all of the Directors of the Company, take the following
actions by unanimous written consent; said actions to have the same force and
effect as if adopted at a meeting of the Board of Directors duly called and
held:

    

     

    WHEREAS,
the Company has determined that it is in the best interests of the Company to
enter into an agreement with Belmont Partners, LLC ('Ttelmont") dated January
2009 (the "Agreement") requiring the Company to provide Belmont a three percent
(3%) common stock shares position in the Company (the "Position"). The Position
shall be based on the capital structure of the Company after Vend-in of I.P.
(taking into account any and all shares issued relating to the Vend-in of I.P,
initial contracts, and initial acquisition of any assets), post reverse stock
split (if any), post initial financing, and after any other initial issuance of
stock (including issuance to the Company's directors and/or officers
(collectively the "Vend-in of I.P.");

    

     

    WHEREAS, the Company has entered into the
Agreement with Belmont;

    

     

    WHEREAS, the Company has received fiill and
adequate consideration from Belmont for the Position;

    

     

    WHEREAS, it is in the best interests of the
Company to issue such shares of the Company's common stock to Belmont as
necessary to provide Belmont the Position according to the terms of the
Agreement;

    

     

    WHEREAS, all shares transferred to Belmont
hereby shall be deemed to have a valuation of par value;

    

     

    NOW,
THEREFORE, IT IS HEREBY RESOLVED AS FOLLOWS:

     

    (a)   it is in
the best interests of the Company to undertake the transactions contemplated
hereby; and

     

    (b)   the
transactions are hereby approved, ratified and confirmed; and

     

    (c)   in
accordance with the Shareholder Consent dated January 28/09 the
Company will issue shares of the Company's common stock to Belmont necessary to
provide Belmont the Position according to the terms of the Agreement;
and

    

    
      
        
        

      

      
        15

        
          

        

      

      
        
        

      

    

     

    
      (d)   any transfer agent
acting for or on behalf of the Company or a Surviving Company (a "Transfer
Agent") shall be entitled to rely upon these resolutions to execute the issuance
of the Position as aforesaid; and

       

      (e)   certificate(s)
evidencing the Position shall be issued and delivered to Belmont Partners, LLC
immediately following the actions anticipated by the Vend-in of I.P., but in no
case later than the eleventh (11th)
month anniversary of the Effective Date of the Stock Purchase Agreement, in the
event that all actions contemplated by the Vend-in of I.P. have not been
completed by the eleventh month anniversary of the Effective Date of the Stock
Purchase Agreement, Belmont Partners, LLC shall be issued shares comprising the
Position on that date and shall be issued additional shares as necessary
following any reverse stock split, share issuances relating to the Vend-in of
I.P. and initial contracts, initial acquisition of any assets, initial
financing, and after any other initial issuance of stock; and

       

      (f)           
the
effective date of all shares transferred pursuant to this Board Resolution shall
be the Effective Date of the Stock Purchase Agreement and shall be memorialized
on the face of the certificates evidencing such shares. Company shall accept as
valid any legal opinion of Belmont Partners, LLC's counsel regarding the removal
of restrictions from all shares hereby issued, and any transfer agent acting on
behalf of the Company shall be entitled to rely upon these resolutions to remove
such restrictions from such shares; and

       

      (g)   the
Company agrees to indemnify and hold harmless the Transfer Agent from and
against any and all claims, liabilities, losses, damages and expenses, including
fees and expenses of counsel, accountants and other advisors (collectively,
"Losses"), related thereto or arising out of or in connection therewith the
issuance of the Position; and

       

      (h)   the
Company gives the Transfer Agent authorization to deliver said shares as specified
herein to Belmont Partners, LLC at 360 Main Street, Washington, Virginia
22747 via Federal Express or Hand Dehvery;
and

    

     

    (i)    the value of
all shares hereby transferred shall be par value.

     

    Each
Director, by signing this Unanimous Written Consent of the Board of Directors in
Lieu of a Special Meeting, waives notice of the time, place and purpose of a
special Board of Directors' meeting and agrees to the transaction of the
business set forth in this unanimous written consent in lieu of such
meeting.

     

    IN WITNESS WHEREOF, we have each signed this
Unanimous Written Consent of the Board of Directors in Lieu of a Special
Meeting, which may be signed in one or more counterparts, each of which, when
taken together, shall constitute one and the same instrument, effective as of
the date executed below.

     

    
      
        	 	
                

              
	 	Date:
      January 28, 2009

      

    

     

    
      
        
        

      

      
        16

        
          

        

      

      
        
        

      

    

    
       

      EXHIBIT
3

       

    

    IRREVOCABLE
TRANSFER AGENT INSTRUCTIONS

    

    TO:    Pacific Stock
Transfer

         
    500 East Warm
Springs Road, Suite 240, Las Vegas, NV 89119

     

    Re:     Clopton
House Corporation

     

     

    Ladies
and Gentlemen:

     

    Reference
is made to that certain Common Stock Purchase Agreement between Clopton House
Corporation (the "Company"), Belmont Partners, LLC ("Belmont") and BT2
International, Inc. (the "Buyer"), dated January, 28 2009 pursuant
to which the Company shall issue to Belmont a number of shares of the common
stock of the Company equal to three percent (3%) of the Company capital stock
(the "Position"). This letter shall serve as the Company's irrevocable
authorization and direction to Pacific Stock Transfer, and to any subsequent
Transfer Agent of the Company , (collectively the "Transfer Agent") to issue
shares of the common stock of the Company to Belmont as set forth below, and no
subsequent direction, order, resolution or other order or request of the Company
shall be effective to rescind, modify, nullify, or otherwise cancel these
instructions, the attached resolutions, or the shares issued
hereby.

     

    Specifically,
the Transfer Agent is hereby instructed to issue three percent (3%) of the
Company's capital to Belmont based on the capital structure of the Company after
Vend-in of I.P. (taking into account any and all shares issued relating to the
Vend-in of I.P., initial contracts, and initial acquisition of any assets), post
reverse stock split (if any), post initial financing, and after any other
initial issuance of stock (including issuance to the Company's directors and/or
officers (collectively, the "Actions").

     

    The
Transfer Agent shall deliver certificate(s) evidencing the shares in the
Position to Belmont Partners, LLC, at the address indicated below immediately
following the Actions, but in no case later than the eleventh month anniversary
of the Effective Date of the Stock Purchase Agreement, In the event that all
Actions have not been completed by the Effective Date of the Stock Purchase
Agreement, the Transfer Agent shall transfer to Belmont certificate(s)
evidencing the shares comprising the Position on the eleventh month anniversary
of the Effective Date of the Stock Purchase Agreement, and shall further issue
additional shares to Belmont as necessary following completion of the
Actions.

     

    The
shares comprising the Position shall be newly issued restricted common shares of
the Company, and the Effective date of all shares in the Position shall be the
Effective Date of the Stock Purchase Agreement regardless of the date on which
the certificate(s) evidencing such shares are issued, and such effective date
shall be evidenced on the face of such certificate(s).

     

    
      
        
        

      

      
        17

        
          

        

      

      
        
        

      

       

      The
Company hereby confirms to the Transfer Agent and Belmont that the shares
comprising the Position shall not be subject to any stop-transfer restrictions
and shall otherwise be freely transferable on the books and records of the
Company, and that if the shares comprising the Position are not registered for
sale under the Securities Act of 1933, as amended, then the certificates
evidencing such shares shall bear the requisite restrictive legend. The Transfer
Agent is hereby instructed to accept as valid any opinion of Belmont's counsel
regarding removal of any restriction from the shares comprising the Position,
and upon receipt of such opinion of counsel the Transfer Agent shall promptly
remove such legend.

       

      The
Company hereby represents, acknowledges and agrees that: (i) Belmont has relied
upon the representations and covenants made by the Company hereunder as a
material inducement to Belmont entering into the Common Stock Purchase
Agreement; (ii) that without such representations and covenants Belmont would
not enter into the Common Stock Purchase Agreement; (iii) in the event of any
breach or threatened breach of any provision hereof, Belmont would be
irreparably damaged and damages at law would be an inadequate remedy if these
Irrevocable Transfer Agent Instructions were not specifically enforced.
Therefore, in the event of a breach or threatened breach of the representations
and covenants, hereunder, or a breach or threatened breach of the Transfer
Agent's duties and obligations herein defined, Belmont shall be entitled in
addition to all other rights and remedies, to an injunction restraining such
breach, without being required to show any actual damages or to post any bond or
other security, and/or to a decree of specific performance of the provisions of
these Irrevocable Transfer Agent Instructions.

       

      Delivery
of the certificate(s) evidencing the Position shall be delivered to Belmont by
Federal Express to Belmont Partners, LLC, 360 Main Street, Washington, Virginia
22747, or to such other address as specified in writing by Belmont.

       

      IN
WITNESS WHEREOF, the Parties have caused this agreement and letter of
Irrevocable Transfer Agent Instructions to be duly executed and delivered as of
the date first written above.

    

     

    

     

    
      
        
        

      

      
        18

        
          

        

      

      
        
        

      

    

     

    EXHIBIT
4 

    WRITTEN
SHAREHOLDERS CONSENT 

    IN
LDZU OF A SPECIAL MEETING

    

    In lieu
of a Special Meeting of the Shareholders of Clopton House Corporation, a
corporation organized in the State of Delaware (the "Company"), the
undersigned, being the majority shareholder(s) of the Company, take the
following actions by unanimous written consent; said actions to have the same
force and effect as if adopted at a meeting of the majority shareholders duly
called and held:

     

    WHEREAS, the Shareholder(s) wish to approve the
issuance of a three percent (3%) common stock share position issued to Belmont
Partners, LLC based upon the capital structure of the Company after Vend-in of
I.P. (taking into account any and all shares issued relating to the Vend-in of
I.P, initial contracts, and initial acquisition of any assets), post reverse
stock split (if any), post initial financing, and after any other initial
issuance of stock (including issuance to the Company's directors and/or
officers).

     

    NOW,
THEREFORE, IT IS HEREBY RESOLVED AS FOLLOWS:

     

    (a)   the
transactions contemplated above are hereby approved, ratified and
confirmed;

     

    (b)   the
Shareholder(s) approve the issuance of a three percent (3%) common stock share
position to Belmont Partners, LLC based upon the capital structure of the
Company after Vend-in of I.P. (taking into account any and all shares issued
relating to the Vend-in of I.P., initial contracts, and initial acquisition of
any assets), post reverse stock split (if any), post initial financing, and
after any other initial issuance of stock (including issuance to the Company's
directors and/or officers).

    
    

     

    Each
Shareholder, by signing this Written Consent of the Shareholders in Lieu of a
Special Meeting, waives notice of the time, place and purpose of a special
Majority Shareholders meeting and agrees to the transaction of the business set
forth in this unanimous written consent in lieu of such meeting.

     

    IN WITNESS WHEREOF, we have each
signed this written consent Shareholders in Lieu of a Special Meeting,
which may be signed in one or more counterparts, each of which, when taken
together, shall constitute one and the same instrument, effective as of the date
executed below. 

       

    

                

     

    
      
        
        

      

      
        19

        
          

        

      

      
        
        

      

    

     

    
      
        
        

      

       

      EXHIBIT 5

      UNANIMOUS
WRITTEN CONSENT 

      OF
THE BOARD OF DIRECTORS 

      IN
LIEU OF A SPECIAL MEETING

    

    

     

    In lieu
of a Special Meeting of the Board of Directors of Clopton House Corporation, a
corporation organized in the State of Delaware (the "Company"), the
undersigned, being all of the Directors of the Company, take the following
actions by unanimous written consent; said actions to have the same force and
effect as if adopted at a meeting of the Board of Directors duly called and
held:

     

    WHEREAS, the Company has determined that it is
in the best interests of the Company to transfer one hundred percent (100%) of
the Company's capital stock to BT2 International, Inc..

     

    NOW,
THEREFORE, IT IS HEREBY RESOLVED AS FOLLOWS:

     

    (a)   it is in
the best interests of the Company to undertake the transaction contemplated
hereby; and,

     

    (b)   the
transactions are hereby approved, ratified and cwrrfirmed; and,

     

    (c)   any
transfer agent acting for or on behalf of the Company or a Surviving Company (a
"Transfer Agent") shall be entitled to rely upon these resolutions to execute
the issuance of the shares as aforesaid; and,

     

    (d)   the
effective date of all Shares transferred pursuant to this Board Resolution shall
be the Effective Date of the Stock Purchase Agreement and shall be memorialized
on the face of the certificates evidencing such shares; and,

     

    (e)   the
Company agrees to indemnify and hold harmless the Transfer Agent from and
against any and all claims, liabilities, losses, damages and expenses, including
fees and expenses of counsel, accountants and other advisors (collectively,
"Losses"), related thereto or arising out of or in connection therewith the
issuance of shares; and,

     

    (f)   the value
of all shares hereby transferred shall be par value.

     

    Each
Director, by signing this Unanimous Written Consent of the Board of Directors in
Lieu of a Special Meeting, waives notice of the time, place and purpose of a
special Board of Directors' meeting and agrees to the transaction of the
business set forth h\ this unanimous written consent in lieu of such
meeting.

     

    IN WITNESS WHEREOF, we have each signed this
Unanimous Written Consent of the Board of Directors in Lieu of a Special
Meeting, which may be signed in one or more counterparts, each of which, when
taken together, shall constitute one and the same instrument, effective as of
the date executed below.

     

                

     

    
      
        
        

      

      
        20

        
          

        

      

      
        
        

      

       

      EXHIBIT 6

      WRITTEN
SHAREHOLDERS CONSENT 

      IN
LIEU OF A SPECIAL MEETING

    

     

    In lieu
of a Special Meeting of the Shareholders of Clopton House Corporation, a
corporation organized in the State of Delaware (the "Company"), the
undersigned, being the majority shareholders) of the Company, take the following
actions by unanimous written consent; said actions to have the same force and
effect as if adopted at a meeting of the majority shareholders duly called and
held:

     

    WHEREAS, the
Shareholder(s) wish to approve the transfer
of one hundred percent (100%) of the Company's capital stock to BT2
International, Inc..

     

    NOW,
THEREFORE, IT IS HEREBY RESOLVED AS FOLLOWS:

     

    (a)   the
transactions contemplated above are hereby approved, ratified and confirmed;
and,

     

    (b)   the Shareholder(s) approve the transfer of
one hundred percent (100%) of the Company's capital stock to BT2 International,
Inc..

     

    Each
Shareholder, by signing this Written Consent of the Shareholders in Lieu of a
Special Meeting, waives notice of the time, place and purpose of a special
Majority Shareholders meeting and agrees to the transaction of the business set
forth in this unanimous written consent in lieu of such meeting. 

     

    IN WITNESS WHEREOF, we have each
signed this written Consent Shareholders in Lieu of a Special Meeting,
which may be signed in one or more counterparts, each of which, when taken
together, shall constitute one and the same instrument, effective as of the date
executed below.

     

                

     

    
      
        
        

      

      
        21

        
          

        

      

      
        
        

      

    

     

    EXHIBIT
7

    UNANIMOUS
WRITTEN CONSENT

    OF
THE BOARD OF DHtECTORS

    IN
LIEU OF A SPECIAL MEETING

    

     

    In lieu
of a Special Meeting of the Board of Directors of Clopton House Corporation, a
corporation organized in the State of Delaware (the "Company"), the undersigned,
being all of the Directors of the Company, take the following actions by
unanimous written consent; said actions to have the same force and effect as if
adopted at a meeting of the Board of Directors duly called and
held;

     

    WHEREAS, the Board wishes to appoint David
Bycbkov as the sole Director and President of the Company; and,

     

    WHEREAS, the Board wishes to accept the
resignation of Joseph Meuse as the sole Director and President of the
Company.

     

    NOW,
THEREFORE, IT IS HEREBY RESOLVED AS FOLLOWS:

     

    (a)           
it
is in the best interests of the Company to undertake the transactions contemplated
hereby; and,

     

    (b)    the
transactions are hereby approved, ratified and confirmed; and,

     

    (c)    the Company
appoints David Bychkov as a Director and the President; and,

     

    (d)   the Company appoints Cheyenne Crow, Joseph
Meuse and Robert Doornick as Directors of the Company; and

     

    (e)   the Company appoints Delbert Blewitt as the
Secretary of the Company and as a Director of the Company;
and

     

    (f)    the Company accepts the resignation of
Joseph Meuse as President and Secretary of the Company.

     

    Each
Director, by signing this Unanimous Written Consent of the Board of Directors in
Lieu of a Special Meeting, waives notice of the time, place and purpose of a
special Board of Directors' meeting and agrees to the transaction of the
business set forth in this unanimous written consent in lieu of such
meeting.

     

    IN WITNESS WHEREOF, we have each signed this
UnanimousyWritten Consent of the Board of Directors in Lieu of a Special Meeting
which may be signed in one or more counterparts, each of which, when taken
together, shall constitute one and the same instrument, effective as
of the date executed below.

                   

     

    
      
        
        

      

      
        22

        
          

        

      

      
        
        

      

       

      EXHIBIT 8

      WRITTEN
SHAREHOLDERS CONSENT 

      IN
LIEU OF A SPECIAL MEETING

    

     

    In lieu
of a Special Meeting of the Shareholders of Clopton House Corporation, a
corporation organized in the State of Delaware (the "Company"), the
undersigned, being the majority shareholder(s) of the Company, take the
following actions by unanimous written consent; said actions to have the same
force and effect as if adopted at a meeting of the majority shareholders duly
called and held:

     

    WHEREAS, the Shareholder(s) wish to nominate of
David Bychkov as the sole Director, President and Secretary of the Company;
and,

     

    WHEREAS, the Shareholder(s) wish to accept the
resignation of Joseph Meuse as the sole Director, President and Secretary of the
Company.

     

    NOW,
THEREFORE, IT IS HEREBY RESOLVED AS FOLLOWS:

     

    (a)   the
transactions contemplated above are hereby approved, ratified and confirmed;
and

     

    (b)   the
Shareholder(s) approve the nomination of David Bychkov as a Director and the
President and,

     

    (c)    the
Shareholder(s) accept the resignation of Joseph Meuse as the President and
Secretary of the Company; and

     

    (d)   appoints
Cheyenne Crow, Joseph Meuse and Robert Doornick as Directors of the Company;
and

     

    (e)    the
Shareholder(s) approve the nomination of Delbert Blewett as a Director and as
the Secretary of the Corporation.

     

    Each
Shareholder, by signing this Written Consent of the Shareholders in Lieu of a
Special Meeting, waives notice of the time, place and purpose of a special
Majority Shareholders meeting and agrees to the transaction of the business set
forth in this unanimous written consent in lieu of such meeting.

     

    IN WITNESS WHEREOF, we have
each signed this written consent of the Shareholders in Lieu of a Special
Meeting, which may be signed in one or more counterparts, each of which, when
taken together, shall constitute one and the same instrument effective as of the
date executed below.

     

                      

     

    
      
        
        

      

      
        23

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00169-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00169-of-00352.parquet"}]]